|
|
Vaccine Detail
|
Neoantigen Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Neoantigen Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: patient specific neo-antigens (NCT05098210; NCIT_C165508)
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is a peptide-based cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. (NCIT_C165508) Personalized neo-antigen peptide vaccine is a product combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor. Patients also receive nivolumab. (NCT05098210)
|
| Host Response |
|
|
| References |
NCIT_C165508: Neoantigen Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C165508]
NCT05098210: Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer [https://clinicaltrials.gov/study/NCT05098210]
|
|
